Table 1. Snapshot of North America Pharmacogenomics Market, 2019-2030 18
Table 2. Web-based Resources of Pharmacogenomics 23
Table 3. Main Product Trends and Market Opportunities in North America Pharmacogenomics Market 33
Table 4. North America Pharmacogenomics Market by Service, 2019-2030, $ mn 41
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing 46
Table 6. North America Pharmacogenomics Market by Technology, 2019-2030, $ mn 48
Table 7. North America Pharmacogenomics Market by Application, 2019-2030, $ mn 56
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry 61
Table 9. North America Pharmacogenomics Market by End User, 2019-2030, $ mn 65
Table 10. North America Pharmacogenomics Market by Country, 2019-2030, $ mn 71
Table 11. U.S. Pharmacogenomics Market by Service, 2019-2030, $ mn 75
Table 12. U.S. Pharmacogenomics Market by Technology, 2019-2030, $ mn 75
Table 13. U.S. Pharmacogenomics Market by Application, 2019-2030, $ mn 75
Table 14. Canada Pharmacogenomics Market by Service, 2019-2030, $ mn 78
Table 15. Canada Pharmacogenomics Market by Technology, 2019-2030, $ mn 78
Table 16. Canada Pharmacogenomics Market by Application, 2019-2030, $ mn 78
Table 17. Mexico Pharmacogenomics Market by Service, 2019-2030, $ mn 80
Table 18. Mexico Pharmacogenomics Market by Technology, 2019-2030, $ mn 80
Table 19. Mexico Pharmacogenomics Market by Application, 2019-2030, $ mn 80
Table 20. Product Approvals by Company, January 2016 April 2019 83
Table 21. Breakdown of North America Market by Key Vendor, 2019, % 83
Table 22. 23andMe, Inc.: Company Snapshot 86
Table 23. 23andMe, Inc.: Business Segmentation 86
Table 24. 23andMe, Inc.: Product Portfolio 87
Table 25. 23andMe, Inc.: Revenue, 2016-2018, $ mn 87
Table 26. 23andMe, Inc.: Recent Developments 87
Table 27. Risk Evaluation for Investing in North America Market, 2019-2030 112
Table 28. Critical Success Factors and Key Takeaways 115

LIST OF FIGURE

Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Pharmacogenomics Market, 2019-2030, $ mn 20
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice 22
Figure 7. Impact of COVID-19 on Business 24
Figure 8. Primary Drivers and Impact Factors of North America Pharmacogenomics Market 26
Figure 9. World Top 10 Causes of Deaths, 2016 29
Figure 10. Primary Restraints and Impact Factors of North America Pharmacogenomics Market 30
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics 32
Figure 12. Investment Opportunity Analysis 34
Figure 13. Porters Fiver Forces Analysis of North America Pharmacogenomics Market 37
Figure 14. Breakdown of North America Pharmacogenomics Market by Service, 2019-2030, % of Revenue 41
Figure 15. North America Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%) 42
Figure 16. North America Pharmacogenomics Market: Genotyping, 2019-2030, $ mn 43
Figure 17. North America Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn 44
Figure 18. North America Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn 45
Figure 19. North America Pharmacogenomics Market: Other Services, 2019-2030, $ mn 47
Figure 20. Breakdown of North America Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue 48
Figure 21. North America Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%) 49
Figure 22. North America Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn 50
Figure 23. North America Pharmacogenomics Market: Microarray, 2019-2030, $ mn 51
Figure 24. North America Pharmacogenomics Market: Sequencing, 2019-2030, $ mn 52
Figure 25. North America Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn 53
Figure 26. North America Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn 54
Figure 27. North America Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn 55
Figure 28. Breakdown of North America Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue 56
Figure 29. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 57
Figure 30. North America Pharmacogenomics Market: Oncology, 2019-2030, $ mn 58
Figure 31. North America Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn 59
Figure 32. North America Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn 60
Figure 33. North America Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn 62
Figure 34. North America Pharmacogenomics Market: Pain Management, 2019-2030, $ mn 63
Figure 35. North America Pharmacogenomics Market: Other Applications, 2019-2030, $ mn 64
Figure 36. Breakdown of North America Pharmacogenomics Market by End User, 2019-2030, % of Revenue 65
Figure 37. North America Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 66
Figure 38. North America Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn 67
Figure 39. North America Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn 68
Figure 40. North America Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn 69
Figure 41. Breakdown of North America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 71
Figure 42. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 72
Figure 43. U.S. Pharmacogenomics Market, 2019-2030, $ mn 74
Figure 44. Canada Pharmacogenomics Market, 2019-2030, $ mn 77
Figure 45. Pharmacogenomics Market in Mexico, 2015-2030, $ mn 79
Figure 46. Growth Stage of North America Pharmacogenomics Industry over the Forecast Period 81